VTVT
NASDAQvTv Therapeutics Inc.
News · 26 weeks34+300%
2026-01-182026-07-12
Mix1890d
- SEC Filings7(39%)
- Insider5(28%)
- Other4(22%)
- Dividends1(6%)
- Analyst1(6%)
Latest news
25 items- PRvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 12,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have a weighted average exercise price of $34.15 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the
- ANALYSTRodman & Renshaw initiated coverage on vTv Therapeutics with a new price targetRodman & Renshaw initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $67.00
- INSIDERSEC Form 4 filed by Director Baker Bros. Advisors Lp4 - vTv Therapeutics Inc. (0001641489) (Issuer)
- SECvTv Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - vTv Therapeutics Inc. (0001641489) (Filer)
- INSIDERSEC Form 4 filed by Director Spiegelman Daniel K4 - vTv Therapeutics Inc. (0001641489) (Issuer)
- INSIDERSEC Form 4 filed by Director Akkaraju Srinivas4 - vTv Therapeutics Inc. (0001641489) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Anne M.4 - vTv Therapeutics Inc. (0001641489) (Issuer)
- INSIDERSEC Form 4 filed by Director Al-Marzooqi Fahed4 - vTv Therapeutics Inc. (0001641489) (Issuer)
- SECSEC Form DEFA14A filed by vTv Therapeutics Inc.DEFA14A - vTv Therapeutics Inc. (0001641489) (Filer)
- PRvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $34.30 per share, which is equal to the closing price of the Company's common stock on June 1, 2026. Each option will vest ov
- SECSEC Form 8-K filed by vTv Therapeutics Inc.8-K - vTv Therapeutics Inc. (0001641489) (Filer)
- SECSEC Form S-8 filed by vTv Therapeutics Inc.S-8 - vTv Therapeutics Inc. (0001641489) (Filer)
- SECSEC Form 10-Q filed by vTv Therapeutics Inc.10-Q - vTv Therapeutics Inc. (0001641489) (Filer)
- SECvTv Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - vTv Therapeutics Inc. (0001641489) (Filer)
- PRvTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePhase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. The Company continues to advance its Phase 3 CATT1 trial, with enrollment on track for completion in the thi
- PRvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 39,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have a weighted average exercise price of $32.00 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the
- PRvTv Therapeutics to Participate in Upcoming May Investor ConferencesHIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in May: H.C. Wainwright 4th Annual BioConnect Investor ConferenceFormat: Fireside Chat & one-on-one investor meetingsDate: Tuesday, May 19, 2026Time: 12:30 PM ETLocation: New York, NYWebcast Link Alliance Global Partners Healthcare Company ShowcaseFormat: Fireside ChatDate: Wednesday, May 20, 2026Time: 4
- SECSEC Form DEF 14A filed by vTv Therapeutics Inc.DEF 14A - vTv Therapeutics Inc. (0001641489) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by vTv Therapeutics Inc.SCHEDULE 13G/A - vTv Therapeutics Inc. (0001641489) (Subject)
- PRvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)HIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 4,000 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $39.54 per share, which is equal to the closing price of the Company's common stock on April 6, 2026. Each option will vest
- SECSEC Form SCHEDULE 13G filed by vTv Therapeutics Inc.SCHEDULE 13G - vTv Therapeutics Inc. (0001641489) (Subject)
- PRvTv Therapeutics to Participate in the 38th Annual ROTH ConferenceHIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in a fireside chat and conduct 1x1 investor meetings at the 38th Annual ROTH Conference, which is being held March 22-24, 2026, in Dana Point, CA. 38th Annual ROTH Conference:Format: Fireside chat and 1x1 investor meetingsDate:Monday, March 23, 2026Time: 10:00 AM PDTWebcast Link A live webcast of the fireside chat will be available on the
- ANALYSTEvercore ISI initiated coverage on vTv Therapeutics with a new price targetEvercore ISI initiated coverage of vTv Therapeutics with a rating of Outperform and set a new price target of $44.00
- SECvTv Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - vTv Therapeutics Inc. (0001641489) (Filer)
- SECvTv Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - vTv Therapeutics Inc. (0001641489) (Filer)
VTVT FAQ
7 questionsWhat does vTv Therapeutics Inc. do?
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and...Where does VTVT stock trade?
vTv Therapeutics Inc. (VTVT) is listed on NASDAQ.What sector and industry is VTVT in?
vTv Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did vTv Therapeutics Inc. go public?
vTv Therapeutics Inc. (VTVT) completed its IPO in 2015.What are analysts saying about VTVT?
vTv Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy on 2026-06-30.What companies are similar to VTVT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VTVT side-by-side with any of them on Quantisnow.How can I track VTVT on Quantisnow?
Quantisnow aggregates vTv Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VTVT to receive live email and push alerts on every new disclosure.